CA2306492C - Human checkpoint kinase, hcds1, compositions and methods - Google Patents

Human checkpoint kinase, hcds1, compositions and methods Download PDF

Info

Publication number
CA2306492C
CA2306492C CA2306492A CA2306492A CA2306492C CA 2306492 C CA2306492 C CA 2306492C CA 2306492 A CA2306492 A CA 2306492A CA 2306492 A CA2306492 A CA 2306492A CA 2306492 C CA2306492 C CA 2306492C
Authority
CA
Canada
Prior art keywords
protein
seq
nucleic acid
acid sequence
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2306492A
Other languages
English (en)
French (fr)
Other versions
CA2306492A1 (en
Inventor
Walter H.M.L. Luyten
Andrew E. Parker
Clare Mcgowan
Alessandra Blasina
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Institute filed Critical Scripps Research Institute
Publication of CA2306492A1 publication Critical patent/CA2306492A1/en
Application granted granted Critical
Publication of CA2306492C publication Critical patent/CA2306492C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/12Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/05Animals comprising random inserted nucleic acids (transgenic)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Dental Preparations (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA2306492A 1997-10-22 1998-10-21 Human checkpoint kinase, hcds1, compositions and methods Expired - Fee Related CA2306492C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9722320.0A GB9722320D0 (en) 1997-10-22 1997-10-22 Human cell cycle checkpoint proteins
GB9722320.0 1997-10-22
PCT/EP1998/006981 WO1999025843A2 (en) 1997-10-22 1998-10-21 Human checkpoint kinase, hcds1, compositions and methods

Publications (2)

Publication Number Publication Date
CA2306492A1 CA2306492A1 (en) 1999-05-27
CA2306492C true CA2306492C (en) 2014-03-25

Family

ID=10820925

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002308013A Abandoned CA2308013A1 (en) 1997-10-22 1998-10-21 Human checkpoint kinase, hcds1, compositions and methods
CA2306492A Expired - Fee Related CA2306492C (en) 1997-10-22 1998-10-21 Human checkpoint kinase, hcds1, compositions and methods

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA002308013A Abandoned CA2308013A1 (en) 1997-10-22 1998-10-21 Human checkpoint kinase, hcds1, compositions and methods

Country Status (13)

Country Link
US (4) US6531312B1 (enExample)
EP (2) EP1025237B1 (enExample)
JP (2) JP4261050B2 (enExample)
AT (2) ATE300619T1 (enExample)
AU (2) AU760544B2 (enExample)
CA (2) CA2308013A1 (enExample)
DE (2) DE69831500T2 (enExample)
DK (2) DK1025237T3 (enExample)
ES (2) ES2245050T3 (enExample)
GB (1) GB9722320D0 (enExample)
IL (2) IL135687A (enExample)
NZ (2) NZ503983A (enExample)
WO (2) WO1999025843A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9722320D0 (en) * 1997-10-22 1997-12-17 Janssen Pharmaceutica Nv Human cell cycle checkpoint proteins
CA2331152A1 (en) * 1998-06-23 1999-12-29 Chugai Seiyaku Kabushiki Kaisha Cell cycle regulating factor
GB9827430D0 (en) * 1998-12-11 1999-02-03 Ludwig Inst Cancer Res Differential expression in primary breast cancer
CA2400785A1 (en) * 2000-02-18 2001-08-23 Lexicon Genetics Incorporated Novel human kinases and polynucleotides encoding the same
AU2001237599A1 (en) * 2000-03-08 2001-09-17 Zealand Pharma A/S Materials and methods relating to the degradation of cdc25a in response to dna damage
CA2406399A1 (en) * 2000-04-20 2001-11-01 Incyte Genomics, Inc. Human kinases
US6323016B1 (en) 2000-06-09 2001-11-27 Pe Corporation (Ny) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
FR2812945B1 (fr) * 2000-08-10 2002-10-04 Aventis Pharma Sa Utilisation de la proteine grf1 et cellules exprimant la proteine grf1 pour le criblage de molecules
US6372468B1 (en) * 2000-09-14 2002-04-16 Pe Corporation (Ny) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
AU2002211305A1 (en) * 2000-12-14 2002-06-24 Pe Corporation (Ny) Isolated human kinase proteins, their encoding nucleic acid molecules, and uses thereof
WO2002051858A2 (en) * 2000-12-22 2002-07-04 Isis Pharmaceuticals, Inc. Antisense modulation of chk2 expression
US6451538B1 (en) * 2000-12-22 2002-09-17 Isis Pharmaceuticals, Inc. Antisense modulation of CHK2 expression
WO2002059325A2 (en) * 2000-12-27 2002-08-01 Lexicon Genetics Incorporated Human kinases and polynucleotides encoding the same
EP1224942A1 (en) * 2001-01-23 2002-07-24 Bernhard Dr. Nieswandt Use of JAQ1 (monoclonal antibody anti GPVI) as a medicament for the protection against thrombotic diseases
EP1947102A1 (en) * 2003-01-09 2008-07-23 Pfizer, Inc. Compositions comprising diazepinoindole derivatives as kinase inhibitors
EP1660503A1 (en) * 2003-08-29 2006-05-31 Pfizer Inc. Naphthalene carboxamides and their derivatives useful as new anti-angiogenic agents
WO2005021554A1 (en) * 2003-08-29 2005-03-10 Pfizer Inc. Thienopyridine-phenylacet amides and their derivatives useful as new anti-angiogenic agents
US8572169B2 (en) * 2006-08-28 2013-10-29 Myspace, Llc System, apparatus and method for discovery of music within a social network
MX2009012054A (es) 2007-05-08 2009-11-19 Schering Corp Metodos de tratamiento que usan formulaciones intravenosas que comprenden temozolomida.
CA2731368C (en) * 2008-08-06 2013-05-14 Pfizer Inc. 6 substituted 2-heterocyclylamino pyrazine compounds as chk-1 inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5443962A (en) * 1993-06-04 1995-08-22 Mitotix, Inc. Methods of identifying inhibitors of cdc25 phosphatase
US5674748A (en) * 1995-03-14 1997-10-07 Thomas Jefferson University Human cyclin-dependent kinase-like proteins and methods of using the same
PL322876A1 (en) * 1995-11-16 1998-03-02 Icos Corp Pik type kinase of cellular cycle control point: materials and methods
US5744349A (en) * 1996-03-05 1998-04-28 Washington University DNA sequences encoding human Myt1 kinase
US6218109B1 (en) * 1997-09-05 2001-04-17 Baylor College Of Medicine Mammalian checkpoint genes and proteins
GB9722320D0 (en) * 1997-10-22 1997-12-17 Janssen Pharmaceutica Nv Human cell cycle checkpoint proteins

Also Published As

Publication number Publication date
WO1999020747A3 (en) 1999-07-01
CA2306492A1 (en) 1999-05-27
IL135687A (en) 2007-07-04
WO1999025843A3 (en) 1999-08-05
US6943013B2 (en) 2005-09-13
AU1232299A (en) 1999-05-10
DK1025237T3 (da) 2005-11-28
DE69831500T2 (de) 2006-06-14
EP1025236B1 (en) 2005-07-27
IL135688A0 (en) 2001-05-20
JP4418103B2 (ja) 2010-02-17
WO1999025843A2 (en) 1999-05-27
US6531312B1 (en) 2003-03-11
EP1025237B1 (en) 2005-09-07
EP1025236A2 (en) 2000-08-09
JP4261050B2 (ja) 2009-04-30
ATE304052T1 (de) 2005-09-15
NZ503965A (en) 2002-03-28
DE69831007T2 (de) 2006-04-20
US7414020B2 (en) 2008-08-19
DE69831007D1 (de) 2005-09-01
GB9722320D0 (en) 1997-12-17
ES2245050T3 (es) 2005-12-16
AU752617B2 (en) 2002-09-26
ES2245807T3 (es) 2006-01-16
US20050180981A1 (en) 2005-08-18
AU2612699A (en) 1999-06-07
US20030017160A1 (en) 2003-01-23
DE69831500D1 (de) 2005-10-13
JP2001523461A (ja) 2001-11-27
CA2308013A1 (en) 1999-04-29
IL135687A0 (en) 2001-05-20
JP2001520037A (ja) 2001-10-30
EP1025237A2 (en) 2000-08-09
AU760544B2 (en) 2003-05-15
WO1999020747A2 (en) 1999-04-29
ATE300619T1 (de) 2005-08-15
IL135688A (en) 2010-04-29
NZ503983A (en) 2002-03-28
DK1025236T3 (da) 2005-10-24
US6413755B1 (en) 2002-07-02

Similar Documents

Publication Publication Date Title
CA2306492C (en) Human checkpoint kinase, hcds1, compositions and methods
US6656716B1 (en) Polypeptide fragments of human PAK5 protein kinase
EP0690876B1 (en) Protein kinases
US5817479A (en) Human kinase homologs
US6190663B1 (en) Human MAP kinase homolog
US6586242B1 (en) TAO protein kinases and methods of use therefor
US5830699A (en) SOK-1 and methods of use
AU2003235055B2 (en) Human checkpoint kinase, HCDS1, compositions and methods
AU6405996A (en) A human map kinase homolog
EP1272640A2 (en) 3714, 16742, 23546, and 13887 novel protein kinase molecules and uses therefor
JPWO2002099110A1 (ja) 細胞周期調節因子

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20181022